X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4542) 4542
Publication (340) 340
Book Review (35) 35
Magazine Article (8) 8
Book Chapter (3) 3
Conference Proceeding (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4480) 4480
female (3222) 3222
middle aged (3076) 3076
oncology (2812) 2812
aged (2764) 2764
taxoids - administration & dosage (2492) 2492
male (2293) 2293
docetaxel (2278) 2278
adult (2270) 2270
index medicus (2231) 2231
antineoplastic combined chemotherapy protocols - therapeutic use (2220) 2220
taxoids - adverse effects (2054) 2054
chemotherapy (1955) 1955
antineoplastic combined chemotherapy protocols - adverse effects (1918) 1918
treatment outcome (1511) 1511
breast neoplasms - drug therapy (1416) 1416
cancer (1268) 1268
taxoids - therapeutic use (1136) 1136
paclitaxel (896) 896
drug administration schedule (868) 868
antineoplastic agents - adverse effects (823) 823
taxoids (817) 817
disease-free survival (759) 759
breast cancer (748) 748
paclitaxel - adverse effects (733) 733
aged, 80 and over (730) 730
lung neoplasms - drug therapy (713) 713
paclitaxel - analogs & derivatives (705) 705
breast neoplasms - pathology (697) 697
paclitaxel - administration & dosage (691) 691
neoplasm staging (685) 685
cisplatin - administration & dosage (676) 676
trial (671) 671
antineoplastic combined chemotherapy protocols - administration & dosage (655) 655
cisplatin (647) 647
pharmacology & pharmacy (630) 630
care and treatment (628) 628
antineoplastic agents - therapeutic use (618) 618
carcinoma, non-small-cell lung - drug therapy (608) 608
antineoplastic agents, phytogenic - adverse effects (589) 589
therapy (585) 585
deoxycytidine - analogs & derivatives (577) 577
medicine & public health (558) 558
fluorouracil - administration & dosage (557) 557
deoxycytidine - administration & dosage (495) 495
survival analysis (494) 494
neoplasm metastasis (493) 493
dose-response relationship, drug (473) 473
neutropenia - chemically induced (464) 464
research (463) 463
survival rate (454) 454
retrospective studies (442) 442
antineoplastic agents - administration & dosage (425) 425
carcinoma (418) 418
antineoplastic agents, phytogenic - therapeutic use (412) 412
survival (406) 406
antineoplastic agents (395) 395
metastasis (393) 393
drug therapy (381) 381
prostatic neoplasms - drug therapy (374) 374
antineoplastic agents, phytogenic - administration & dosage (370) 370
paclitaxel - therapeutic use (363) 363
disease progression (362) 362
cisplatin - adverse effects (360) 360
clinical trials (359) 359
antimitotic agents (354) 354
combination (353) 353
prostate cancer (345) 345
hematology, oncology and palliative medicine (344) 344
lung neoplasms - pathology (336) 336
doxorubicin (331) 331
gemcitabine (328) 328
phase-ii trial (325) 325
neoplasms - drug therapy (323) 323
kaplan-meier estimate (320) 320
adenocarcinoma - drug therapy (319) 319
infusions, intravenous (317) 317
chemotherapy, adjuvant (315) 315
capecitabine (312) 312
cancer research (308) 308
deoxycytidine - adverse effects (306) 306
toxicity (303) 303
fluorouracil - adverse effects (301) 301
carcinoma, non-small-cell lung - pathology (297) 297
fluorouracil (296) 296
stomach neoplasms - drug therapy (295) 295
drug resistance, neoplasm (292) 292
carboplatin (285) 285
prognosis (285) 285
cyclophosphamide - administration & dosage (284) 284
analysis (276) 276
quality of life (271) 271
combined modality therapy (269) 269
follow-up studies (268) 268
prospective studies (268) 268
carboplatin - administration & dosage (264) 264
doxorubicin - administration & dosage (261) 261
animals (257) 257
pharmacology/toxicology (251) 251
5-fluorouracil (250) 250
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4135) 4135
Japanese (188) 188
Chinese (65) 65
German (52) 52
French (50) 50
Russian (18) 18
Spanish (13) 13
Italian (12) 12
Hungarian (7) 7
Polish (3) 3
Czech (2) 2
Danish (2) 2
Lithuanian (2) 2
Dutch (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 7/2015, Volume 23, Issue 7, pp. 1969 - 1977
Weekly or tri-weekly docetaxel treatment mandates the use of dexamethasone to prevent toxicity. However, the adverse effects of prophylactic steroid use are... 
Infection | Pain Medicine | Hyperglycemia | Nursing | Rehabilitation Medicine | Corticosteroids | Medicine & Public Health | Docetaxel | Oncology | Nursing Management/Nursing Research | GLUCOCORTICOID-INDUCED HYPERGLYCEMIA | DEXAMETHASONE | TAXANE TOXICITIES | ACUTE LYMPHOCYTIC-LEUKEMIA | PHASE-II | BREAST-CANCER | DIABETES-MELLITUS | WEEKLY PACLITAXEL | INDUCTION THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | STEROID USE | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Breast Neoplasms - drug therapy | Infection - chemically induced | Young Adult | Antineoplastic Agents, Hormonal - adverse effects | Taxoids - administration & dosage | Hyperglycemia - chemically induced | Adult | Female | Aged | Retrospective Studies | Taxoids - adverse effects | Cohort Studies | Antimitotic agents | Complications and side effects | Usage | Chemotherapy | Dexamethasone | Antibiotics | Blood sugar | Antineoplastic agents | Risk factors | Cancer | Side effects | Infections | Steroids | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2011, Volume 11, Issue 6, pp. 349 - 356
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 6, pp. 1537 - 1547
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
Journal Article
Journal Article